Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

PURPOSE: Patients with Ewing sarcoma (ES) with metastases and those who relapse fare poorly and receive therapies that carry significant toxicity. This phase 1/2 study was conducted to evaluate the efficacy of figitumumab in advanced ES. PATIENTS AND METHODS: Patients with sarcoma 10 to 18 years old...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Juergens, Heribert, Daw, Najat C., Geoerger, Birgit, Ferrari, Stefano, Villarroel, Milena, Aerts, Isabelle, Whelan, Jeremy, Dirksen, Uta, Hixon, Mary L., Yin, Donghua, Wang, Tao, Green, Stephanie, Paccagnella, Luisa, Gualberto, Antonio
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2011
الموضوعات:
Original Reports
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236653/
https://ncbi.nlm.nih.gov/pubmed/22025154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.0670
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة